To include your compound in the COVID-19 Resource Center, submit it here.
Oxford BioMedica plc (LSE:OXB) stopped a U.S. Phase II trial of TroVax in patients with metastatic hormone-refractory
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury